From: Therapeutic advancement of chronic lymphocytic leukemia
Reference (year) | Regimen | Number of patients | Median age (years) | CR,% | ORR,% | Median PFS (months) | OS |
---|---|---|---|---|---|---|---|
Rai, 2000 [4] | Chlorambucil | 181 | 62 | 4 | 37 | 14 | Median 56 m |
 | Fludarabine | 170 | 64 | 20 | 63 | 20 | Median 66 m |
Eichhorst, 2009 [5] | Chlorambucil | 100 | 70 | 0 | 51 | 18 | Median 64 m |
 | Fludarabine | 93 | 71 | 7 | 72 | 19 | Median 46 m |
Knauf, 2009 [7] | Chlorambucil | 157 | 66 | 2 | 31 | 8.3 | NR |
 | Bendamustine | 162 | 63 | 31 | 68 | 21.6 | NR |
Eichhorst, 2006 [9] | Fludarabine | 164 | 59 | 7 | 83 | 20 | 81% at 3 y |
 | FC | 164 | 58 | 24 | 94 | 48 | 80% at 3 y |
Catovsky, 2007 [10] | Fludarabine | 194 | 64 | 15 | 80 | 23 | 52% at 5 y |
 | FC | 196 | 65 | 38 | 94 | 43 | 54% at 5 y |
 | Chlorambucil | 387 | 65 | 7 | 72 | 20 | 59% at 5 y |
Flinn, 2007 [11] | Fludarabine | 137 | 61 | 5 | 60 | 19 | 80% at 2 y |
 | FC | 141 | 61 | 23 | 74 | 32 | 79% at 2 y |
Robak, 2010 [13] | CC | 192 | 58 | 47 | 88 | 28 | 62.4% at 4 y |
 | FC | 203 | 59 | 46 | 82 | 27 | 60.6% at 4 y |
Robak, 2011 [15] | Cladribine | 174 | 61 | 21 | 78 | 27.2 | Median 45 m |
 | CC | 171 | 62 | 29 | 83 | 22.4 | Median 48 m |
 | CMC | 163 | 59 | 36 | 80 | 25.6 | Median 46 m |